Neurocysticercosis (NCC) is an infection of the central nervous system caused by the larval form of the tapeworm *Taenia solium*. Infections occur following the accidental ingestion of tapeworm ova found in human feces. NCC is a major cause of epilepsy and disability in many of the world’s poorer countries where families raise free-roaming pigs that are able to ingest human feces. It is frequently diagnosed in immigrant populations in the United States and Canada, reflecting the high endemicity of the infection in their countries of origin [1].

Until recently, NCC and echinococcosis were referred to as “neglected” diseases, but are now recognized by the World Health Organization (WHO) as “major neglected diseases” [2]. In many endemic communities, NCC is the cause of epilepsy in ≥1% of the population. Here, we provide an update of the importance of NCC, recent epidemiological observations, and an outline of the goals of a recently formed group of physicians, the Neurocysticercosis Clinical Research Consortium (NACC).

NCC is difficult to identify and treat. Diagnosis requires brain imaging, a technology commonly unavailable in resource-poor areas, and clinical diagnosis is unreliable, as the manifestations are diverse and non-specific. Additionally, treatment commonly involves weeks to months of medication with close monitoring for side effects and serial brain imaging. NCC is a significant health problem in Latin American countries (LAC), Haiti, sub-Saharan Africa (SSA), India, Southeast Asia, China, Indonesia, and other regions less well categorized, such as New Guinea and Eastern Europe [2]. Although accurate estimates of the extent of infection and disease are not available for most endemic regions, many studies suggest a higher prevalence of infection and disease burden than has been appreciated by experts [3,4].

Conventional diagnosis of NCC requires a compatible clinical history, positive serology, and typical computed tomography (CT) or magnetic resonance imaging (MRI) [5]. Determination of the prevalence of infection is hampered by variable sensitivity and specificity of each of the diagnostic tests, which identify a limited or overlapping proportion of the “true” prevalence of infection. For instance, the sensitivity of the serum electroimmunotransfer blot decreases dramatically in those with calcified disease or a single parenchymal cyst [6] and may be falsely positive in persons exposed but not infected.

Better estimates of infection can be obtained by imaging of the brain to ensure inclusion of individuals with NCC infection who are asymptomatic and seronegative to *T. solium* (see Box 1). One study in Peru that characterized prevalence of infection and NCC using a combination of CT imaging, positive serology, and history of seizures to identify infections [7] reported an NCC seroprevalence of 24%. An additional 13% of those with negative serology had CT scans demonstrating calcifications typical of NCC. Adding the observed proportion of seropositive individuals to seronegative individuals with CT imaging evidence of NCC yields an overall prevalence of cysticercosis of 37%. Even this substantial proportion of infection likely underestimates its prevalence in this population. Applying similar calculations to earlier comparable studies performed in Ecuador [8], Honduras [9], and Mexico [10] yields prevalence estimates of infection of 23%, 38%, and 13%, respectively. Therefore, estimates of prevalence

---

**Neurocysticercosis: Neglected but Not Forgotten**

Christina M. Coyle\(^1\), Siddhartha Mahanty\(^2\), Joseph R. Zunt\(^3\), Mitchell T. Wallin\(^4,5\), Paul T. Cantey\(^6\), A. Clinton White Jr.\(^7\), Seth E. O’Neal\(^8\), Jose A. Serpa\(^9\), Paul M. Southern\(^10\), Patricia Wilkins\(^4\), Anne E. McCarthy\(^11\), Elizabeth S. Higgs\(^12\), Theodore E. Nash\(^13\)*

---

1 Albert Einstein College of Medicine, Bronx, New York, United States of America, 2 Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 3 Departments of Neurology and Global Health, University of Washington, Seattle, Washington, United States of America, 4 Department of Neurology, Georgetown University, Washington, D.C., United States of America, 5 University of Maryland, Baltimore, Maryland, United States of America, 6 Pediatric Diseases Branch, Centers for Disease Control, Atlanta, Georgia, United States of America, 7 Department of Internal Medicine, Infectious Disease Division, University of Texas, Galveston, Texas, United States of America, 8 Oregon Health & Sciences University, Portland, Oregon, United States of America, 9 Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, United States of America, 10 Pathology and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America, 11 Department of Medicine, Ottawa General Hospital, Ottawa, Ontario, Canada, 12 Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 13 Gastrointestinal Parasites Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

---

**Citation:** Coyle CM, Mahanty S, Zunt JR, Wallin MT, Cantey PT, et al. (2012) Neurocysticercosis: Neglected but Not Forgotten. PLoS Negl Trop Dis 6(5): e1500. doi:10.1371/journal.pntd.0001500

**Editor:** Dirk Engels, World Health Organization, Switzerland

**Published:** May 29, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

**Funding:** Funding for this work was provided in part by the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health and by and the Office of Rare Diseases, National Center for Advancing Translational Sciences, NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders financially supported the formation of the consortium (e.g., paid for initial meeting), and communication between the members.

**Competing Interests:** The authors have declared that no competing interests exist.

---

* E-mail: christina.coyle@einstein.yu.edu (CC); tnash@niaid.nih.gov (TEN)
other common infections in LAC [3]. The population currently at risk. These numbers also allow a more appropriate comparison between prevalence estimates of other common infections in LAC [3].

Our estimate of the prevalence of NCC in LAC is substantially higher than that suggested by Bern et al. [11], which estimated asymptomatic NCC only, using fairly conservative assumptions. An estimate of mostly active epilepsy was determined by Bern et al. by subtracting the epilepsy rates in non-endemic regions from rates in endemic regions in Peru [11]. Extrapolating to the 1993 population at risk and adjusting for disease other than seizures, the authors calculated that 400,000 individuals in LAC had symptomatic NCC. More recent studies using direct determinations of active epilepsy due to NCC from active epilepsy rates ranging from 0.6% to 1.8% suggest that between 450,000 and 1.35 million persons suffer from epilepsy due to NCC in LAC (Table 1).

Similar to Latin America, many areas of Asia are endemic for NCC. Studies in endemic regions of India reveal high burdens of infection and symptomatic NCC [2]. In a community study in southern India, the seroprevalence of *T. solium* infection was 15.9%, active epilepsy was present in 3.83/1,000 persons, and 28.4% of these individuals had NCC detected by CT imaging. Extrapolating these figures to the overall population in India suggests that approximately 1 million cases of epilepsy are due to NCC [12]. Cysticercosis is also highly endemic in southwest China. According to a recent WHO report, the average prevalence of *T. solium* infection in China was 0.11% (range, 0.05%–15%); the estimated number of patients with taeniasis was 1.26 million; and the estimated number of cysticercosis cases was 3–6 million [2].

Although SSA is among the least studied regions, accumulating evidence suggests highly endemic transmission with significant symptomatic disease. High prevalence in pigs in many areas suggests a high level of human taeniasis [13,14]. Serologic studies suggest many regions of SSA have endemic infection that likely affects large proportions of the population (Table 2 - adapted from Winkler et al. [4]). Epilepsy prevalence in SSA ranges from 5.2 to 74.4 per 1,000 persons. A recent systematic analysis of the proportion of epilepsy endemic regions due to NCC was estimated at 29% (95% CI: 22.9–35.5) [15]. Using this figure, the prevalence of seizures due to NCC in SSA would be 1.7–24.8 per 1,000 persons.

Reports of NCC in the United States and Canada have also been increasing over the past 50 years, and these reports mostly reflect disease in Hispanic immigrants [16–18]. Regional estimates in the general population range from 0.2 to 0.6 per 100,000 in Oregon and Los Angeles [18,19]. Of those presenting to urban emergency departments because of seizures, 2.1% were attributable to NCC [18], similar to the proportion of seizure patients with NCC (2%) in Houston [16]. This population also presents with complicated subarachnoid disease, or racemose cysticercosis, which is characterized by cysts that proliferate, enlarge, and develop membranes in the subarachnoid spaces of the brain, mostly involving the basilar cisterns and spine. Sequelae include hydrocephalus, arachnoiditis, infarction, and entrapment syndromes requiring long-term corticosteroids, antihelmintics, and serial imaging. These individuals are frequently referred to tertiary care centers where they may be under the care of NACC participants.

Recognizing the importance of NCC in immigrant communities from endemic regions in North America, a group of infectious disease and travel medicine practitioners have come together to focus efforts on management of NCC. The goals of the NACC are to disseminate information regarding diagnosis and treatment of NCC, highlight areas of research need, and advance knowledge through retrospective and prospective collaborative studies of treatment for the more complicated forms of NCC. Initially, we are developing standardized methods to evaluate neuroimaging and morbidity and hope to develop guidelines for treatment.

### Table 1. Estimated Numbers of Persons Infected with Neurocysticercosis or Epilepsy due to Neurocysticercosis by Region.

| Geographic Region | Number Infected | Number with NCC* | Number with Epilepsy due to NCC* |
|-------------------|-----------------|------------------|-------------------------------|
| Latin America     | 11–29 million   | 14.9 million     | 0.45–1.35 million             |
| India             | -               | -                | 1 million                     |
| China             | 3–7 million     | -                | 0.3–0.7 million²              |
| Africa            | -               | -                | 0.31–4.6 million²             |

*See text for methods used to derive these estimates.

²Assumes that 10% of those seropositive to *T. solium* have epilepsy. [Extraction of data from manuscripts summarized in references (7,11,31)]. Seizure rates in populations seropositive to *T. solium* were greater than in seronegative populations by approximately 9.4% (range 1.7–31.3%). Therefore, we assumed 10% of seizures were attributable to NCC in Chinese seropositive populations.

³Assuming 1/3 of the SSA population of 560 million at risk. doi:10.1371/journal.pntd.0001500.t001
In summary, recent carefully performed studies of the prevalence and burden of disease have recognized NCC as a major cause of epilepsy in endemic regions and a cause of complicated brain disease in immigrant populations. Resources directed at defining high prevalence regions, preventing infection, and treating epilepsy and other complications, all achievable with present technology, and would reduce the burden of this debilitating disease worldwide.

References

1. Wallin MT, Kurtzke JF (2004) Neurocysticercosis in the United States: review of an important emerging infection. Neurology 63: 1559–1564.
2. Savioit LS, Baumert D (2010) First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. Geneva: World Health Organisation 2010; 1. pp. 1–169.
3. Hotze PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR (2008) The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2: e200. doi:10.1371/journal.pntd.0000200.
4. Winkler AS, Willingham AL, 3rd, Sikasunge CS, Hotez PJ, Bottazzi ME, Franco-Paredes C (2004) Neurocysticercosis as a major cause of epilepsy in endemic regions and a disease burden from neurocysticercosis in a developing country. Clin Infect Dis 29: 1203–1209.
5. Rajsekhar V, Raghava MV, Prabhakaran V, Oomen A, Mahul J (2006) Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India. Neurology 67: 2135–2139.
6. Zoli AP, Nguekam, Shey-Njila O, Nsengyiumva G, Dorny P, et al. (2007) Combined use of an antigen and antibody detection enzyme-linked immunosorbent assay for cysticercosis as tools in an epidemiological study of epilepsy in Burundi. Trop Med Int Health 12: 895–901.
7. Del Brutto OH, Rajsekhar V, Murrell KD, Oomen A (2004) Taenia solium metacestode glycoproteins as diagnostic antigens for solitary cysticercus granuloma in Indian patients. Trans R Soc Trop Med Hyg 98: 478–484.
8. Montano SM, Villaran MV, Yéquimbiche I, Figueroa JJ, Rodríguez S, et al. (2005) Neurocysticercosis association between seizures, serology, and brain CT in rural Peru. Neurology 65: 229–233.
9. Medina MT, Duron RM, Martinez L, Oorio JR, Estrada AL, et al. (2003) Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia 46: 583–587.
10. Medina MT, Duron RM, Martinez L, Oorio JR, Estrada AL, et al. (2003) Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia 46: 124–131.
11. Fleury A, Gomez T, Alvarez I, Meza D, Huerta M, et al. (2003) High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 22: 139–145.
12. Fleury A, Gomez T, Alvarez I, Meza D, Huerta M, et al. (2003) High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 22: 139–145.
13. Zoli AP, Nguekam, Shey-Njila O, Nsengyiumva G, Dorny P, et al. (2007) Combined use of an antigen and antibody detection enzyme-linked immunosorbent assay for cysticercosis as tools in an epidemiological study of epilepsy in Burundi. Trop Med Int Health 12: 895–901.
14. del la Garza Y, Graviss EA, Daver NG, Youngs T, et al. (2005) Neurocysticercosis in Oregon, 1995–2000. Emerg Infect Dis 10: 508–510.
15. Neill PB, Taran DJ, Nyerere J, Msonda M, et al. (2004) Serologic Studies of Human Cysticercosis/Neurocysticercosis in Sub-Saharan Africa. www.plosntds.org 3 May 2012 | Volume 6 | Issue 5 | e1500